Develops synthetic biotic medicines for metabolic and inflammatory diseases, focusing on engineering probiotic bacteria.
Synlogic, Inc. is a clinical-stage biopharmaceutical firm based in Cambridge, Massachusetts, specializing in the research and development of synthetic biotic medicines aimed at treating metabolic and immunological disorders across the United States. The company's robust pipeline includes several advanced therapeutic programs such as SYNB1618 and SYNB1934, both orally administered candidates currently undergoing Phase II clinical trials for phenylketonuria. Additionally, SYNB1353, another orally administered drug candidate, is being developed to treat homocystinuria, while SYNB2081 targets the reduction of uric acid for potential gout treatment. SYNB8802, currently in Phase I clinical trials, addresses enteric hyperoxaluria with an orally administered approach.
Innovatively, Synlogic, Inc. is also pioneering SYNB1891, an intratumorally administered synthetic biotic medicine in Phase I clinical trials for the treatment of solid tumors and lymphoma. The company has strategically partnered with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to collaboratively research and develop a synthetic biotic medicine for inflammatory bowel disease. Additionally, Synlogic collaborates with Ginkgo Bioworks, Inc. in advancing its groundbreaking therapeutic solutions.
Founded on cutting-edge biotechnological expertise, Synlogic, Inc. continues to expand its capabilities and therapeutic reach through its strategic partnerships and innovative research initiatives. With its headquarters in Cambridge, Massachusetts, the company remains committed to addressing unmet medical needs through its pioneering synthetic biotic medicines.